{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:44:55Z","timestamp":1792035895935,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taoyuan Armed Forces General Hospital","award":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"],"award-info":[{"award-number":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"]}]},{"name":"Taoyuan Armed Forces General Hospital","award":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"],"award-info":[{"award-number":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"]}]},{"name":"Taoyuan Armed Forces General Hospital","award":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"],"award-info":[{"award-number":["TYAFGH-A-111008, TYAFGH-A-112006, TYAFGH-A-113007"]}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"],"award-info":[{"award-number":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"],"award-info":[{"award-number":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"],"award-info":[{"award-number":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"],"award-info":[{"award-number":["NSTC 111-2811-B-400-029; NSTC 112-2320-B-400-008; NSTC 112-2314-B-400-031; NSTC 112-2314-B-037-128"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CS-110-PP-03; CS-111-PP-03; CS-113-SP-04"],"award-info":[{"award-number":["CS-110-PP-03; CS-111-PP-03; CS-113-SP-04"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Caffeic acid phenethyl ester (CAPE) is the main bioactive component of poplar type propolis. We previously reported that treatment with caffeic acid phenethyl ester (CAPE) suppressed the cell proliferation, tumor growth, as well as migration and invasion of prostate cancer (PCa) cells via inhibition of signaling pathways of AKT, c-Myc, Wnt and EGFR. We also demonstrated that combined treatment of CAPE and docetaxel altered the genes involved in glycolysis and tricarboxylic acid (TCA) cycle. We therefore suspect that CAPE treatment may interfere glucose metabolism in PCa cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seahorse Bioenergetics platform was applied to analyzed the extra cellular acidification rate (ECAR) and oxygen consumption rate (OCR) of PCa cells under CAPE treatment. UPLC-MSMS with Multiple Reaction Monitoring (MRM), PCR, and western blot were used to analyze the effects of CAPE on metabolites, genes, and proteins involved in glycolysis, TCA cycle and pentose phosphate pathway in PCa cells. Flow cytometry and ELISA were used to determine the level of reactive oxygen species in PCa cells being treated with CAPE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seahorse Bioenergetics analysis revealed that ECAR, glycolysis, OCR, and ATP production were elevated in C4-2B cells under CAPE treatment. Protein levels of glucose-6-phosphate dehydrogenase (G6PD), phosphogluconate dehydrogenase (PGD), glutaminase (GLS), phospho-AMPK Thr172 as well as abundance of pyruvate, lactate, ribulose-5-phosphate, and sedoheptulose-7-phosphate were increased in CAPE-treated C4-2B cells. ROS level decreased 48\u00a0h after treatment with CAPE. Co-treatment of AMPK inhibitor with CAPE exhibited additive growth inhibition on PCa cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study indicated that PCa cells attempted to overcome the CAPE-induced stress by upregulation of glycolysis and G6PD but failed to impede the growth inhibition caused by CAPE. Concurrent treatment of CAPE and inhibitors targeting glycolysis may be effective therapy for advanced PCa.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13477-6","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:03:33Z","timestamp":1737018213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prostate cancer cells elevate glycolysis and G6PD in response to caffeic acid phenethyl ester-induced growth inhibition"],"prefix":"10.1186","volume":"25","author":[{"given":"Tzu-Ping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Yu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chih","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Li","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jane","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyh-Chyuan","family":"Hour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Pin","family":"Chuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"3","key":"13477_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3322\/canjclin.52.3.154","volume":"52","author":"BA Hellerstedt","year":"2002","unstructured":"Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52(3):154\u201379.","journal-title":"CA Cancer J Clin"},{"key":"13477_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-18-63","volume":"18","author":"CP Chuu","year":"2011","unstructured":"Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci. 2011;18: 63.","journal-title":"J Biomed Sci"},{"issue":"8","key":"13477_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"13477_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.apsb.2018.04.007","volume":"8","author":"B Bumbaca","year":"2018","unstructured":"Bumbaca B, Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B. 2018;8(4):518\u201329.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"13477_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1758834012449685","volume":"4","author":"C Hwang","year":"2012","unstructured":"Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol. 2012;4(6):329\u201340.","journal-title":"Ther Adv Med Oncol"},{"issue":"21","key":"13477_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"26","key":"13477_CR7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"13477_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"13477_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271\u201386.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"13477_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338.","journal-title":"N Engl J Med"},{"issue":"25","key":"13477_CR11","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","volume":"36","author":"G Attard","year":"2018","unstructured":"Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME, collaborators P. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36(25):2639\u201346.","journal-title":"J Clin Oncol"},{"issue":"9\u201310","key":"13477_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1515\/znc-2000-9-1018","volume":"55","author":"M Velikova","year":"2000","unstructured":"Velikova M, Bankova V, Marcucci MC, Tsvetkova I, Kujumgiev A. Chemical composition and biological activity of propolis from Brazilian meliponinae. Z Naturforsch C J Biosci. 2000;55(9\u201310):785\u20139.","journal-title":"Z Naturforsch C J Biosci"},{"issue":"6","key":"13477_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1248\/cpb.51.740","volume":"51","author":"S Kumazawa","year":"2003","unstructured":"Kumazawa S, Yoneda M, Shibata I, Kanaeda J, Hamasaka T, Nakayama T. Direct evidence for the plant origin of Brazilian propolis by the observation of honeybee behavior and phytochemical analysis. Chem Pharm Bull (Tokyo). 2003;51(6):740\u20132.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"5\u20136","key":"13477_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1515\/znc-2002-5-622","volume":"57","author":"V Bankova","year":"2002","unstructured":"Bankova V, Popova M, Bogdanov S, Sabatini AG. Chemical composition of European propolis: expected and unexpected results. Z Naturforsch C J Biosci. 2002;57(5\u20136):530\u20133.","journal-title":"Z Naturforsch C J Biosci"},{"issue":"19","key":"13477_CR15","first-page":"4528","volume":"53","author":"RS Bhimani","year":"1993","unstructured":"Bhimani RS, Troll W, Grunberger D, Frenkel K. Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res. 1993;53(19):4528\u201333.","journal-title":"Cancer Res"},{"issue":"17","key":"13477_CR16","doi-asserted-by":"publisher","first-page":"9090","DOI":"10.1073\/pnas.93.17.9090","volume":"93","author":"K Natarajan","year":"1996","unstructured":"Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A. 1996;93(17):9090\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"13477_CR17","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.3390\/ijms14035264","volume":"14","author":"HP Lin","year":"2013","unstructured":"Lin HP, Lin CY, Liu CC, Su LC, Huo C, Kuo YY, Tseng JC, Hsu JM, Chen CK, Chuu CP. Caffeic acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. Int J Mol Sci. 2013;14(3):5264\u201383.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"13477_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1940-6207.CAPR-12-0004-T","volume":"5","author":"CP Chuu","year":"2012","unstructured":"Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause RJ Jr, Hiipakka RA, Liao S, Jones RB. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and akt signaling networks. Cancer Prev Res (Phila). 2012;5(5):788\u201397.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9","key":"13477_CR19","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.18632\/oncotarget.3246","volume":"6","author":"HP Lin","year":"2015","unstructured":"Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015;6(9):6684\u2013707.","journal-title":"Oncotarget"},{"issue":"2","key":"13477_CR20","doi-asserted-by":"publisher","first-page":"e31286","DOI":"10.1371\/journal.pone.0031286","volume":"7","author":"HP Lin","year":"2012","unstructured":"Lin HP, Jiang SS, Chuu CP. Caffeic acid phenethyl ester causes p21 induction, akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS One. 2012;7(2):e31286.","journal-title":"PLoS One"},{"issue":"25","key":"13477_CR21","doi-asserted-by":"publisher","first-page":"38010","DOI":"10.18632\/oncotarget.9380","volume":"7","author":"JC Tseng","year":"2016","unstructured":"Tseng JC, Lin CY, Su LC, Fu HH, Yang SD, Chuu CP. CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling. Oncotarget. 2016;7(25):38010\u201324.","journal-title":"Oncotarget"},{"key":"13477_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154860","volume":"116","author":"JC Tseng","year":"2023","unstructured":"Tseng JC, Wang BJ, Wang YP, Kuo YY, Chen JK, Hour TC, Kuo LK, Hsiao PJ, Yeh CC, Kao CL, et al. Caffeic acid phenethyl ester suppresses EGFR\/FAK\/Akt signaling, migration, and tumor growth of prostate cancer cells. Phytomedicine. 2023;116: 154860.","journal-title":"Phytomedicine"},{"issue":"1","key":"13477_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12929-022-00797-z","volume":"29","author":"YK Fu","year":"2022","unstructured":"Fu YK, Wang BJ, Tseng JC, Huang SH, Lin CY, Kuo YY, Hour TC, Chuu CP. Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference. J Biomed Sci. 2022;29(1):16.","journal-title":"J Biomed Sci"},{"key":"13477_CR24","first-page":"145","volume":"5","author":"P Jozwiak","year":"2014","unstructured":"Jozwiak P, Forma E, Brys M, Krzeslak A. O-GlcNAcylation and metabolic reprograming in cancer. Front Endocrinol (Lausanne). 2014;5:145.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"13477_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neo.2020.12.009","volume":"23","author":"F Marcucci","year":"2021","unstructured":"Marcucci F, Rumio C. Glycolysis-induced drug resistance in tumors-a response to danger signals? Neoplasia. 2021;23(2):234\u201345.","journal-title":"Neoplasia"},{"issue":"1","key":"13477_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12885-018-4123-1","volume":"18","author":"T Wang","year":"2018","unstructured":"Wang T, Ning K, Sun X, Zhang C, Jin LF, Hua D. Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer. BMC Cancer. 2018;18(1):207.","journal-title":"BMC Cancer"},{"issue":"3","key":"13477_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/cells9030668","volume":"9","author":"N Lorito","year":"2020","unstructured":"Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, et al. Glucose metabolic reprogramming of ER breast cancer in acquired resistance to the CDK4\/6 inhibitor palbociclib(). Cells. 2020;9(3):668.","journal-title":"Cells"},{"issue":"9","key":"13477_CR28","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/blood-2008-05-157842","volume":"113","author":"E Hulleman","year":"2009","unstructured":"Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113(9):2014\u201321.","journal-title":"Blood"},{"issue":"29","key":"13477_CR29","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","volume":"8","author":"X Qian","year":"2017","unstructured":"Qian X, Xu W, Xu J, Shi Q, Li J, Weng Y, Jiang Z, Feng L, Wang X, Zhou J, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget. 2017;8(29):47691\u2013708.","journal-title":"Oncotarget"},{"issue":"4","key":"13477_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41419-019-1549-6","volume":"10","author":"T Shi","year":"2019","unstructured":"Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F, Liu C, Zhang G, Wang Z, Wang R, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308.","journal-title":"Cell Death Dis"},{"issue":"1","key":"13477_CR31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41467-019-10374-y","volume":"10","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Li CF, Ruan D, He J, Montal ED, Lorenz S, Girnun GD, Chan CH. Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion. Nat Commun. 2019;10(1):2625.","journal-title":"Nat Commun"},{"issue":"27","key":"13477_CR32","doi-asserted-by":"publisher","first-page":"10530","DOI":"10.1074\/jbc.RA119.007784","volume":"294","author":"N Lypova","year":"2019","unstructured":"Lypova N, Telang S, Chesney J, Imbert-Fernandez Y. Increased 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. J Biol Chem. 2019;294(27):10530\u201343.","journal-title":"J Biol Chem"},{"key":"13477_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lfs.2018.12.055","volume":"218","author":"HJ Cardoso","year":"2019","unstructured":"Cardoso HJ, Vaz CV, Carvalho TMA, Figueira MI, Socorro S. Tyrosine kinase inhibitor imatinib modulates the viability and apoptosis of castrate-resistant prostate cancer cells dependently on the glycolytic environment. Life Sci. 2019;218:274\u201383.","journal-title":"Life Sci"},{"issue":"16","key":"13477_CR34","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-17-3226","volume":"78","author":"J Liu","year":"2018","unstructured":"Liu J, Chen G, Liu Z, Liu S, Cai Z, You P, Ke Y, Lai L, Huang Y, Gao H, et al. Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer. Cancer Res. 2018;78(16):4459\u201370.","journal-title":"Cancer Res"},{"key":"13477_CR35","doi-asserted-by":"publisher","unstructured":"Siltari A, Syvala H, Lou YR, Gao Y, Murtola TJ. Role of lipids and lipid metabolism in prostate cancer progression and the tumor\u2019s immune environment. Cancers (Basel). 2022;14(17):4293. https:\/\/doi.org\/10.3390\/cancers14174293.","DOI":"10.3390\/cancers14174293"},{"issue":"4","key":"13477_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/nu14040851","volume":"14","author":"JC Pardo","year":"2022","unstructured":"Pardo JC, Ruiz de Porras V, Gil J, Font A, Puig-Domingo M, Jorda M. Lipid metabolism and epigenetics crosstalk in prostate cancer. Nutrients. 2022;14(4):851.","journal-title":"Nutrients"},{"issue":"2","key":"13477_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbcan.2019.01.001","volume":"1871","author":"V Strmiska","year":"2019","unstructured":"Strmiska V, Michalek P, Eckschlager T, Stiborova M, Adam V, Krizkova S, Heger Z. Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer. 2019;1871(2):248\u201358.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"13477_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fphys.2017.00097","volume":"8","author":"F Cutruzzola","year":"2017","unstructured":"Cutruzzola F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, Paone A. Glucose metabolism in the progression of prostate cancer. Front Physiol. 2017;8:97.","journal-title":"Front Physiol"},{"issue":"1","key":"13477_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2008.10.001","volume":"275","author":"CP Chuu","year":"2009","unstructured":"Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 2009;275(1):86\u201392.","journal-title":"Cancer Lett"},{"issue":"2","key":"13477_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149481","volume":"11","author":"S Lemma","year":"2016","unstructured":"Lemma S, Avnet S, Salerno M, Chano T, Baldini N. Identification and validation of housekeeping genes for gene expression analysis of cancer stem cells. PLoS One. 2016;11(2): e0149481.","journal-title":"PLoS One"},{"issue":"3","key":"13477_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/CCLM.2003.040","volume":"41","author":"S Gelmini","year":"2003","unstructured":"Gelmini S, Tricarico C, Petrone L, Forti G, Amorosi A, Dedola GL, Serio M, Pazzagli M, Orlando C. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med. 2003;41(3):261\u20135.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"13477_CR42","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1002\/ctm2.764","volume":"12","author":"CY Lin","year":"2022","unstructured":"Lin CY, Wang BJ, Fu YK, Huo C, Wang YP, Chen BC, Liu WY, Tseng JC, Jiang SS, Sie ZL, et al. Inhibition of KDM4C\/c-Myc\/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism. Clin Transl Med. 2022;12(3):e764.","journal-title":"Clin Transl Med"},{"key":"13477_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10894","volume":"7","author":"S Nobrega-Pereira","year":"2016","unstructured":"Nobrega-Pereira S, Fernandez-Marcos PJ, Brioche T, Gomez-Cabrera MC, Salvador-Pascual A, Flores JM, Vina J, Serrano M. G6PD protects from oxidative damage and improves healthspan in mice. Nat Commun. 2016;7: 10894.","journal-title":"Nat Commun"},{"issue":"9606","key":"13477_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64\u201374.","journal-title":"Lancet"},{"issue":"2","key":"13477_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"13477_CR46","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48(7):e245.","journal-title":"Exp Mol Med"},{"issue":"44","key":"13477_CR47","doi-asserted-by":"publisher","first-page":"27879","DOI":"10.1074\/jbc.271.44.27879","volume":"271","author":"SA Hawley","year":"1996","unstructured":"Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem. 1996;271(44):27879\u201387.","journal-title":"J Biol Chem"},{"key":"13477_CR48","doi-asserted-by":"publisher","unstructured":"Song J, Sun H, Zhang S, Shan C. The multiple roles of glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance. Life (Basel). 2022;12(2):271. https:\/\/doi.org\/10.3390\/life12020271.","DOI":"10.3390\/life12020271"},{"issue":"1","key":"13477_CR49","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41467-018-02950-5","volume":"9","author":"FL Li","year":"2018","unstructured":"Li FL, Liu JP, Bao RX, Yan G, Feng X, Xu YP, Sun YP, Yan W, Ling ZQ, Xiong Y, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun. 2018;9(1):508.","journal-title":"Nat Commun"},{"key":"13477_CR50","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.2147\/OTT.S242929","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Li Y, Fang F. MiR-138 suppresses the PDK1 expression to decrease the oxaliplatin resistance of colorectal cancer. Onco Targets Ther. 2020;13:3607\u201318.","journal-title":"Onco Targets Ther"},{"key":"13477_CR51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2020.03.015","volume":"479","author":"Y Xi","year":"2020","unstructured":"Xi Y, Yuan P, Li T, Zhang M, Liu MF, Li B. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 2020;479:112\u201322.","journal-title":"Cancer Lett"},{"issue":"15","key":"13477_CR52","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/onc.2016.370","volume":"36","author":"T Yu","year":"2017","unstructured":"Yu T, Yang G, Hou Y, Tang X, Wu C, Wu XA, Guo L, Zhu Q, Luo H, Du YE, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP\/PKA\/CREB\/glycolytic axis to confer tumor cells with multidrug resistance. Oncogene. 2017;36(15):2131\u201345.","journal-title":"Oncogene"},{"issue":"2","key":"13477_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jcb.22422","volume":"109","author":"M Wartenberg","year":"2010","unstructured":"Wartenberg M, Richter M, Datchev A, Gunther S, Milosevic N, Bekhite MM, Figulla HR, Aran JM, Petriz J, Sauer H. Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem. 2010;109(2):434\u201346.","journal-title":"J Cell Biochem"},{"key":"13477_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12964-015-0114-x","volume":"13","author":"W Wagner","year":"2015","unstructured":"Wagner W, Ciszewski WM, Kania KD. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun Signal. 2015;13:36.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"13477_CR55","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","volume":"28","author":"M Apicella","year":"2018","unstructured":"Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernandez-Perez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, et al. Increased lactate secretion by Cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;28(6):848-865 e846.","journal-title":"Cell Metab"},{"issue":"6","key":"13477_CR56","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.celrep.2016.04.029","volume":"15","author":"E Allen","year":"2016","unstructured":"Allen E, Mieville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR Signaling. Cell Rep. 2016;15(6):1144\u201360.","journal-title":"Cell Rep"},{"issue":"45","key":"13477_CR57","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1038\/onc.2017.227","volume":"36","author":"HQ Ju","year":"2017","unstructured":"Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo HY, Chen Y, Tian T, Wang Y, Kang TB, et al. Disrupting G6PD-mediated redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 2017;36(45):6282\u201392.","journal-title":"Oncogene"},{"issue":"1","key":"13477_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13277-011-0251-9","volume":"33","author":"J Wang","year":"2012","unstructured":"Wang J, Yuan W, Chen Z, Wu S, Chen J, Ge J, Hou F, Chen Z. Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol. 2012;33(1):95\u2013101.","journal-title":"Tumour Biol"},{"issue":"1","key":"13477_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbapap.2018.05.005","volume":"1867","author":"R Nagashio","year":"2019","unstructured":"Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, et al. Prognostic significance of G6PD expression and localization in lung adenocarcinoma. Biochim Biophys Acta Proteins Proteom. 2019;1867(1):38\u201346.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"4","key":"13477_CR60","first-page":"1703","volume":"53","author":"X Chen","year":"2018","unstructured":"Chen X, Xu Z, Zhu Z, Chen A, Fu G, Wang Y, Pan H, Jin B. Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro. Int J Oncol. 2018;53(4):1703\u201312.","journal-title":"Int J Oncol"},{"issue":"3","key":"13477_CR61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11060-018-2911-8","volume":"139","author":"CA Yang","year":"2018","unstructured":"Yang CA, Huang HY, Lin CL, Chang JG. G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity. J Neurooncol. 2018;139(3):661\u201370.","journal-title":"J Neurooncol"},{"issue":"4","key":"13477_CR62","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/abbs\/gmy009","volume":"50","author":"M Lu","year":"2018","unstructured":"Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L, Wang L, Zhu W, Jia H. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 2018;50(4):370\u201380.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"10","key":"13477_CR63","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ejso.2015.08.155","volume":"41","author":"X Wang","year":"2015","unstructured":"Wang X, Li X, Zhang X, Fan R, Gu H, Shi Y, Liu H. Glucose-6-phosphate dehydrogenase expression is correlated with poor clinical prognosis in esophageal squamous cell carcinoma. Eur J Surg Oncol. 2015;41(10):1293\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"13477_CR64","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13046-019-1164-5","volume":"38","author":"L Mele","year":"2019","unstructured":"Mele L, la Noce M, Paino F, Regad T, Wagner S, Liccardo D, Papaccio G, Lombardi A, Caraglia M, Tirino V, et al. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. J Exp Clin Cancer Res. 2019;38(1):160.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"13477_CR65","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-07-0091","volume":"13","author":"R Bedolla","year":"2007","unstructured":"Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and akt activation. Clin Cancer Res. 2007;13(13):3860\u20137.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"13477_CR66","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","volume":"96","author":"LC Cantley","year":"1999","unstructured":"Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway. Proc Natl Acad Sci U S A. 1999;96(8):4240\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5308","key":"13477_CR67","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943\u20137.","journal-title":"Science"},{"issue":"15","key":"13477_CR68","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-08-0125","volume":"15","author":"D Sarker","year":"2009","unstructured":"Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K\/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15(15):4799\u2013805.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"13477_CR69","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1158\/1078-0432.CCR-04-0477","volume":"10","author":"G Ayala","year":"2004","unstructured":"Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004;10(19):6572\u20138.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"13477_CR70","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1158\/0008-5472.CAN-04-0272","volume":"64","author":"JI Kreisberg","year":"2004","unstructured":"Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphorylation of akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64(15):5232\u20136.","journal-title":"Cancer Res"},{"issue":"6","key":"13477_CR71","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/sj.bjc.6604152","volume":"98","author":"P McCall","year":"2008","unstructured":"McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer. 2008;98(6):1094\u2013101.","journal-title":"Br J Cancer"},{"issue":"4","key":"13477_CR72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/path.2559","volume":"218","author":"K Sircar","year":"2009","unstructured":"Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009;218(4):505\u201313.","journal-title":"J Pathol"},{"issue":"5930","key":"13477_CR73","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333.","journal-title":"Science"},{"issue":"3","key":"13477_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297\u2013308.","journal-title":"Cancer Cell"},{"issue":"20","key":"13477_CR75","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18(20):5546\u201353.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13477-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:55:50Z","timestamp":1737021350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13477-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13477"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13477-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}